RxDoctor Payments Data

Rebecca Hebard, APRN

Nurse Practitioner · Inverness, FLNPI 1821708520

Payments from drug & device makers

$3,666in general payments, 2019–2025

Across 149 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$533
  • AstraZeneca$524
  • Pfizer$454
  • Lexicon Pharmaceuticals, Inc.$272
  • Merck$267
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$265
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,666 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$31,531
Medicare patients
260
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$190,378
FarxigaDapagliflozin Propanediol156$178,908
EntrestoSacubitril/Valsartan94$140,278
JardianceEmpagliflozin81$106,522
XareltoRivaroxaban71$77,539
Repatha SureclickEvolocumab65$61,960
Repatha SyringeEvolocumab49$38,768
BrilintaTicagrelor16$17,041
Metoprolol Succinate581$7,306
Isosorbide Dinitrate93$4,811
Clonidine11$3,987
ClopidogrelClopidogrel Bisulfate235$3,701
Ranolazine ErRanolazine36$3,543
Diltiazem 12hr ErDiltiazem Hcl13$3,408
Midodrine Hcl26$2,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$524$195,949172 claims
PfizerEliquis$454$190,378164 claims
NovartisEntresto$110$140,27894 claims
Boehringer IngelheimJardiance$256$106,52281 claims
Johnson & JohnsonXarelto$203$77,53971 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Inverness

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →